Nicola Gebbia

Studio di phase II: Docetaxel settimanale come seconda linea chemioterapia nel carcinoma prostatico avanzato.

Vincenzo Serretta, Nicolo' Gebbia, Darvinio Melloni, 2006 .

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.

Laura La Paglia, Giuseppe Colucci, Vincenzo Adamo, 2010, Cancer treatment reviews.

STAT proteins: From normal control of cellular events to tumorigenesis

Nicola Gebbia, Maria Buscemi, A. Russo, 2003, Journal of cellular physiology.